RIGHT OF USE AGREEMENTRight of Use Agreement • May 28th, 2021 • Castle Creek Biosciences, Inc. • Pharmaceutical preparations • Illinois
This Right of Use Agreement (“Agreement”), effective as of November 1, 2019 (the “Effective Date”), is by and between Paragon Biosciences, LLC, a Delaware limited liability company (“Paragon”), and Castle Creek Pharmaceuticals, LLC, a Delaware limited liability company (the “Portfolio Company”).
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • May 28th, 2021 • Castle Creek Biosciences, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of October 5, 2012 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and FIBROCELL SCIENCE, INC., a Delaware corporation having its principal place of business at 405 Eagleview Boulevard, Exton, PA 19341 (“Fibrocell”). Intrexon and Fibrocell may be referred to herein individually as a “Party”, and collectively as the “Parties.”
FIRST AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • May 28th, 2021 • Castle Creek Biosciences, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT is entered into as of this 28th day of June, 2013 and serves to amend the Exclusive Channel Collaboration Agreement entered into by and between Intrexon Corporation (“Intrexon”) and Fibrocell Science, Inc. (“Fibrocell”), on October 5, 2012 (the “Agreement”). All capitalized terms not defined herein shall have the meaning set forth in the Agreement.
SECOND AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • May 28th, 2021 • Castle Creek Biosciences, Inc. • Pharmaceutical preparations • Illinois
This SECOND AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENT (this “Agreement”), dated as of October 9, 2018 (the “Effective Date”), is by and among Paragon Biosciences, LLC, a Delaware limited liability company (the “Management Company”), Castle Creek Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), and, solely with respect to Section 6 herein, Jeffrey S. Aronin (“Aronin”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth Section 9 of this Agreement.
AMENDMENT TO LEASELease • May 28th, 2021 • Castle Creek Biosciences, Inc. • Pharmaceutical preparations • Pennsylvania
THIS AMENDMENT TO LEASE (the “Amendment”), is effective as of April 1, 2011, and is by and between THE HANKIN GROUP (“Landlord”) and FIBROCELL SCIENCE, INC., formerly known as ISOLAGEN, INC. (“Tenant”).
LEASE FOR COMBINATION OFFICE/WAREHOUSE AT EAGLEVIEW CORPORATE CENTER BUILDING NO. LANDLORD: THE HANKIN GROUP TENANT: ISOLAGEN, INC.Castle Creek Biosciences, Inc. • May 28th, 2021 • Pharmaceutical preparations
LEASE is made this 7th day of April, 2005 between THE HANKIN GROUP, a Pennsylvania limited partnership (“Landlord”), with its office at Eagleview Corporate Center, 707 Eagleview Boulevard, P.O. Box 562, Exton, Pennsylvania 19341, and ISOLAGEN, INC., a Delaware corporation (“Tenant”), with its office at 2500 Wilcrest, 5th Floor, Houston, TX 77042.
CONFIDENTIALCastle Creek Biosciences, Inc. • May 28th, 2021 • Pharmaceutical preparations
This letter (the “Agreement”) will confirm our understanding that Paragon Health Capital, LLC (“PHC”) has been hired to serve as the financial advisor to Castle Creek Biosciences, LLC and/or its affiliates, subsidiaries or related companies that exist today or which may be created by you (“CCB” or the “Company”). This Agreement supersedes all prior agreements with CCB.
Re: “Exclusive Channel Collaboration Agreement” executed Oct. 5, 2012 by and between Fibrocell Science, Inc. (“Fibrocell”) and Intrexon Corporation (“Intrexon”), as amended and as further amended and modified by that certain letter agreement, dated...Letter Agreement • May 28th, 2021 • Castle Creek Biosciences, Inc. • Pharmaceutical preparations
This letter agreement constitutes the Termination and Modification Agreement as defined in the Letter Agreement, pursuant to which the Parties shall mutually agree to terminate the ECC, convert the ECC into a product license between Fibrocell and Precigen with regard to the Retained Products and clarify certain items. Please note that, per our recent public announcement, Intrexon has officially been renamed Precigen, Inc. (“Precigen”) and has assigned and consolidated its human health therapeutic development operations, including all of its operations relevant to the ECC, to and within its wholly owned subsidiary PGEN Therapeutics, Inc. (“PGEN”). Unless otherwise specified, references to Fibrocell in this Termination and Modification Agreement shall refer to both Fibrocell and its parent, Castle Creek Biosciences, Inc. (“CCB”), and references to Precigen in this Termination and Modification Agreement shall be deemed to encompass references to Intrexon prior to its having been renamed P
THIRD AMENDMENT TO LEASELease • May 28th, 2021 • Castle Creek Biosciences, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO LEASE (the “Amendment”) is effective as of May 11, 2021, and is by and between HANKIN GROUP, a Pennsylvania limited partnership (“Landlord”) and CASTLE CREEK BIOSCIENCES, INC., a Delaware corporation (“Tenant”).
20374 Seneca Meadows Pkwy Germantown, MD 20876 precigen.com February 19, 2020 Fibrocell Science, Inc. c/o Castle Creek Biosciences, Inc.Channel Collaboration Agreement • May 28th, 2021 • Castle Creek Biosciences, Inc. • Pharmaceutical preparations
